Clinical Trial Update: Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Study of ABT-652 in Subjects With Excessive Daytime Sleepiness [Phase 1]

View source ↗

Summary

Phase 1 clinical trial update evaluating safety, tolerability, pharmacokinetics and pharmacodynamics of ABT-652 in subjects with excessive daytime sleepiness.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Sleep Disorders

Drugs mentioned

• ABT-652

Snippet

Sponsor: Abbott | Conditions: Sleep Disorder | Phase 1 | Status: COMPLETED